

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



EC Healthcare

醫思健康

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2138)

GRANT OF SHARE OPTIONS

This announcement is made pursuant to Rule 17.06A of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The board (the “**Board**”) of directors (the “**Directors**” and each a “**Director**”) of EC Healthcare (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces that on 5 January 2023, the Company granted the options (the “**Share Options**”) to 1 employee (the “**Grantee**”), subject to acceptance by the Grantee, under the share option scheme adopted by the Company on 19 February 2016 (the “**Share Option Scheme**”). The Grantee is a member of the senior management of the Group and the director of a number of subsidiaries of the Company. Details of Share Options granted are as follows:

Date of Grant:	5 January 2023
Exercise price of Share Options granted:	HK\$9.00 per share of the Company (the “ Share ”) for the aggregate of 900,000 Share Options granted to the Grantee, and HK\$10.00 per Share for the aggregate of 900,000 Share Options granted to the Grantee, which are: <ul style="list-style-type: none">(i) higher than the closing price of HK\$8.40 per Share as stated in the daily quotation sheets issued by the Stock Exchange on the date of grant of the Share Options, i.e. 5 January 2023;(ii) higher than the average closing price of HK\$7.982 per Share as stated in the daily quotation sheets issued by the Stock Exchange for the five (5) business days immediately preceding the date of grant of the Share Options; and(iii) higher than the nominal value of HK\$0.00001 per Share.

Number of Share Options granted:	An aggregate of 1,800,000 Share Options to the Grantee (each Share Option shall entitle the holder thereof to subscribe for one (1) Share).
Vesting schedule of the Share Option:	<p>The details of the vesting schedule for the Grantee are as follows:</p> <ul style="list-style-type: none"> (i) 300,000 of the Share Options with exercise price of HK\$9.00 shall vest on the Grantee on 5 January 2024, and shall be exercisable until 4 January 2033 (both dates inclusive); (ii) 300,000 of the Share Options with exercise price of HK\$9.00 shall vest on the Grantee on 5 January 2025, and shall be exercisable until 4 January 2033 (both dates inclusive); (iii) 300,000 of the Share Options with exercise price of HK\$9.00 shall vest on the Grantee on 5 January 2026, and shall be exercisable until 4 January 2033 (both dates inclusive); (iv) 300,000 of the Share Options with exercise price of HK\$10.00 shall vest on the Grantee on 5 January 2027, and shall be exercisable until 4 January 2033 (both dates inclusive); (v) 300,000 of the Share Options with exercise price of HK\$10.00 shall vest on the Grantee on 5 January 2028, and shall be exercisable until 4 January 2033 (both dates inclusive); and (vi) 300,000 of the Share Options with exercise price of HK\$10.00 shall vest on the Grantee on 5 January 2029, and shall be exercisable until 4 January 2033 (both dates inclusive).
Performance target and claw back mechanism:	<p>There is no performance target nor clawback mechanism attached to the Share Options.</p> <p>The purpose of the Share Option Scheme is to provide incentive for the grantees for their contribution to the Group. Having considered that (i) the Grantee is a member of the senior management team of the Group who will contribute directly to the overall business performance and sustainable development of the Group and (ii) the exercise price represents certain premium over the existing market price of the Shares and will only be vested in six tranches from January 2024 – January 2029, the Remuneration Committee believes that the grant of the Options could</p>

align the interests of the Grantee with that of the Company and the Shareholders, provide incentives to the core management team to devote to the future continuous competitiveness, results of operation and growth of the Company, and reinforce the core management team's commitment to long term services of the Company, which is in line with the aforesaid purpose of the Share Option Scheme.

Financial assistance: The Group has not provided any financial assistance to the Grantee to facilitate the purchase of shares under the Share Option Scheme.

To the best knowledge, information and belief of the Directors, having made all reasonable enquiries, the Grantee is not (i) a Director, chief executive nor substantial shareholder of the Company nor an associate (as defined under the Listing Rules) of any of them; (ii) a participant with options granted and to be granted exceeding the 1% individual limit under Rule 17.03D of the Listing Rules; or (iii) a related entity participant or service provider.

After grant of the Share Options, the number of Shares available for future grant under the Share Option Scheme is 57,207,500.

By order of the Board
EC Healthcare
Raymond Siu
Company Secretary

Hong Kong, 5 January 2023

As at the date of this announcement, the executive Directors are Mr. Tang Chi Fai, Mr. Lu Lyn Wade Leslie, Mr. Lee Heung Wing, Ms. Wong Ka Ki Ada and Mr. Wong Chi Cheung, the non-executive Director is Mr. Luk Kun Shing Ben, and the independent non-executive Directors are Mr. Ma Ching Nam, Mr. Look Andrew and Mr. Au Tsun.